now browsing by category
Oncotarget is a free access journal that publishes research article online on a weekly basis. This journal is committed to disseminating scientific information promptly. Oncotarget works in collaboration with other partners, including Wellcome Trust Publishers and PubMed. In the last couples of years, this journal has become famous in the scientific world due to its multiple peer-review, constructive, insightful, and punctual research works and more information click here.
Oncotarget serves to increase the impact of research. It publishes papers in the disciplines such as:
- Autophagy and cell death
- Immunology and Microbiology
Oncotarget is flexible and can post each article based on customer demand. This journal serves to minimize the gap between various specialties, allowing findings to be disseminated quickly to maximize the impact of research. Additionally, Oncotarget serves to merge the different fields of medicine, and foster the adoption new clinical sciences to fight illnesses. This journal is involved in sponsoring various research and scientific meetings. Oncotarget is the principal sponsor of the Gordon Research Conference, a meeting recently held on July 2017 at the University of New England. Mr. Howard Crawford and Mr. Rama Khokha chaired this conference and Oncotarget on Facebook.
The leadership of the journal
Dr. Mikhail Blagosklonny and Andrei V. Gudkov founded Oncotarget. These two scientists work at the Roswell Park Cancer Institute, Buffalo, New York. Dr. Mikhail Blagosklonny is an expert in hematology, oncology, and clinical trials. He has authored over 279 research items, which have since acquired over 10,487 reads and 24,213 citations. Dr. Mikhail Blagosklonny’s expertise ranges from cancer metastasis, chemoprevention, cell invasion, and senescence. This expert is a senior editor of numerous journals, including Oncotarget, Cancer Biology & Therapy, Cancer Research, PLoS ONE, the International Journal of Cancer, and the American Journal of Pathology.
Under Dr. Mikhail Blagosklonny’s management, this company has won numerous awards, including the Breakthrough Prize, one of the most prestigious awards in science. Oncotarget also works with other renowned scientists, including Stephen J. Elledge, Bert Vogelstein, Michael N. Hall, and Alexander Varshavsky. Oncotarget is considering increasing its publication frequency through publishing more than two papers per week. This idea came about due to the growing demand for knowledge. Oncotarget is expected to liaise with PubMed to actualize this idea and learn more about Oncotarget.
Eric Lefkofsky is a graduate of the University of Michigan Law School. He is the Co-founder and the CEO of Tempus, a technology company that initiated an operating system for battling cancer. The company gives a platform for physicians to interact and learn on how to give a personalized care to cancer patients by gathering, sorting and analyzing data from previous cancer patients. This data enables the physicians to make decisions to the benefit of the current cancer patients.
In the course of his career, Eric Co-founded Uptake in 2014, an analytic company that empowers companies to increase their performance while reducing failure of assets. Since 2007, Eric has been Co-founder and Chairman of Groupon, a local e-commerce Company. In 2010, he Co-founded Lightbank, a capital firm specializing in disruptive technology where they invest more than money. In 2006, he founded MediaBank which forms a platform for agencies to organize their advertising process. He is the co-founder of echo global logistics, inner workings and mediaocean.
Eric is a professor at the University of Chicago and an author of Accelerated disruption. He explains accelerated disruption as the process of using technology to implement disruptive businesses that are convenient and offering better prices. Eric gives some tips to entrepreneurs on how they can form disruptive businesses and make it a realistic idea. Business development is moved at the speed of the current technological advancements and learn more about Eric.
As part of his philanthothropic work, Eric and his wife established a charitable foundation known as Lefkofsky Family Foundation. The foundation advances initiatives for enhancing lives of communities through promoting all forms of community education, sensitizing Americans on fundamental human rights, promoting medical education and skills and promoting arts and culture for the community. Eric is a trustee of Lurie Children’s Hospital in Chicago and more information click here.
Eric was born in 1969 from Detroit, Michigan, United States. He is an Entrepreneur. He has his profiles in the social media where you can easily learn more about his entrepreneurship. His twitter handle is @ Lefkofsky. His Facebook page can be liked at @eplefkofsky. His profile can too be viewed in linked in and Eric’s lacrosse camp.
More visit: https://www.tempus.com/about-us/
Over the past few years, cancer has become epidemic and continues to claim many lives. Research has found out a close relationship between aging and cancer. Of interest to many researchers is the relationship between an individual’s genetic makeup and their predisposition to any cancer and more information click here.
Tempus, a startup that is keen on making significant headways in the battle against cancer has set shop at the University of Chicago. Under a partnership that was negotiated by the founder of the startup, billionaire Eric Lefkofsky, the firm is expected to supply the University of Chicago’s Medicine Faculty with relevant data on patients with breast cancer.
According to cancer.org, over a quarter a million individuals are diagnosed to be having breast cancer every year in the United States alone. 90 percent of those diagnosed are women and close to 50,000 people succumb to breast cancer every year. Cancer is proving to be the thorn in the flesh of most medical professionals.
Part of the reason why more effective treatments for cancer have not been achieved is that not much research has been done to compare individual patient’s genomic sequence and how they respond to different remedies. This eventuality leaves the doctors with fewer data to deduce from whenever they are recommending a medical procedure to people who are battling cancer and learn more about Eric.
Eric Lefkofsky has done it in other industries. He has built successful enterprises that leverage big data to provide useful analytics to businesses. Eric is keen on using the same approach in dealing with cancer. Over a period of less than a year, Lefkofsky’s firm, Tempus will aggregate phenotypic and genomic data on 1,000 cancer patients and deliver it to the medical experts at the University of Chicago for further analysis.
Other than Tempus, Eric Lefkofsky is the man behind several businesses. Groupon is an e-commerce site that Eric founded together with his friend Brad Keywell. Groupon alongside other enterprises such as Drivin and Lightbank have enabled Eric to create a lot of fortunes in the corporate world and Eric’s lacrosse camp.
Eric Lefkofksy is also involved in charities that try to create opportunities for the downtrodden and disadvantaged members of the society and Eric’s Twitter.